Table 2. Total estimated drug treatment cost and rankings.
| List price rank | Estimated treatment cost rank | Active substance | Form and strength of drug substance | Number of cycles (3 weeks) | Treatment duration | Estimated treatment cost |
|---|---|---|---|---|---|---|
| 31 | 1 | Bevacizumab | Injection fluid 25mg/ml 0.15 ml | 15.1 | Mean TL | €174,399.68 |
| 5 | 2 | Bevacizumab | Concentrate for solution infusion 25mg/ml 16 ml | 15.1 | Mean TL | €51,836.10 |
| 2 | 3 | Trastuzumab emtansine | Powder for solution infusion 160 mg | 9.5 | Median TL | €44,505.75 |
| 28 | 4 | Everolimus | Dispersible tablet 5 mg | 8.0 | Mean TL | €31,207.25 |
| 12 | 5 | Trastuzumab | Powder for solution infusion 150 mg | 13.0 | Mean TL | €21,947.45 |
| 25 | 6 | Everolimus | Tablet 10 mg | 8.0 | Mean TL | €21,254.31 |
| 36 | 7 | Lapatinib | Tablet 250 mg | 15.0 | Median TL | €18,682.30 |
| 1 | 8 | Pertuzumab | Concentrate for solution infusion 30mg/ml 14 ml | 4.5 | Mean TL | €16,665.64 |
| 3 | 9 | Trastuzumab | Injection fluid 120mg/ml 5 ml | 13.0 | Mean TL | €16,286.10 |
| 7 | 10 | Thiotepa* | Powder for solution infusion 100 mg | 7.6 | Assumption | €14,467.30 |
| 32 | 11 | Vinblastin* | Injection fluid 1mg/ml 10 ml | 7.6 | Assumption | €10,175.00 |
| 6 | 12 | Doxorubicin* | Concentrate for solution infusion 2mg/ml 25 ml | 4.3 | Median PFS | €9,950.96 |
| 11 | 13 | Eribulin* | Injection fluid 0,44mg/ml 3 ml | 4.8 | Mean TL | €8,551.01 |
| 14 | 14 | Paclitaxel* | Powder for solution infusion 100 mg | 5.6 | Mean TL | €8,024.00 |
| 10 | 15 | Doxorubicin* | Powder for solution infusion 50 mg | 4.3 | Median PFS | €6,354.32 |
*
generic drugs
If an assumption was used to estimate the average treatment length, this assumption was based on the average treatment length of all other drugs for which a treatment length was available in the EPARs or ZINL assessment reports. Mean TL = Mean treatment length. median PFS = Median progression-free survival